ALXO trades 161.4% below Wall Street's consensus target of $4.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes ALXO achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 7 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 21, 2026, ALX Oncology Holdings Inc. (ALXO) has a Wall Street consensus price target of $4.00, based on estimates from 7 covering analysts. With the stock currently trading at $1.53, this represents a potential upside of +161.4%. The company has a market capitalization of $83M.
Analyst price targets range from a low of $4.00 to a high of $4.00, representing a 0% spread in expectations. The median target of $4.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 6 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, ALXO trades at a trailing P/E of -0.8x. Analysts expect EPS to grow +62.5% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
FATEFate Therapeutics, Inc. | $244M | $2.09 | $5.50 | +163.2% | Buy | — | 31 |
IMVTImmunovant, Inc. | $7.3B | $35.34 | $45.00 | +27.3% | Buy | — | 23 |
RCUSArcus Biosciences, Inc. | $2.4B | $24.31 | $31.00 | +27.5% | Buy | — | 18 |
AGENAgenus Inc. | $125M | $3.00 | $7.33 | +144.3% | Buy | 3.8x | 11 |
NKTRNektar Therapeutics | $1.2B | $60.98 | $149.60 | +145.3% | Buy | — | 33 |
MGNXMacroGenics, Inc. | $263M | $4.13 | $6.00 | +45.3% | Buy | — | 22 |
EXELExelixis, Inc. | $13.2B | $51.91 | $47.33 | -8.8% | Buy | 14.7x | 32 |
HALOHalozyme Therapeutics, Inc. | $8.1B | $68.55 | $88.25 | +28.7% | Buy | 8.5x | 27 |
TGTXTG Therapeutics, Inc. | $8.1B | $53.22 | $54.50 | +2.4% | Buy | 38.6x | 13 |
KYMRKymera Therapeutics, Inc. | $7.4B | $90.43 | $112.60 | +24.5% | Buy | — | 26 |
Quick answers to the most common questions about buying ALXO stock.
The consensus Wall Street price target for ALXO is $4, representing 161.4% upside from the current price of $1.53. With 7 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
ALXO has a consensus rating of "Buy" based on 7 Wall Street analysts. The rating breakdown is predominantly bullish, with 6 Buy/Strong Buy ratings. The consensus 12-month price target of $4 implies 161.4% upside from current levels.
ALXO's current price is $1.53 with a consensus target of $4 (161.4% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $4 for ALXO, while the most conservative target is $4. The consensus of $4 represents the median expectation. These targets typically reflect 12-month expectations.
ALXO is moderately covered, with 7 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 6 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month ALXO stock forecast based on 7 Wall Street analysts shows a consensus price target of $4, with estimates ranging from $4 (bear case) to $4 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on ALXO, with a "Buy" consensus rating and $4 price target (161.4% upside). 6 of 7 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
ALXO analyst price targets range from $4 to $4, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $4 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.